News

Filter

Current filters:

RegeneronZaltrap

1 to 9 of 12 results

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Regeneron posts strong growth for 2012, beating analysts' estimates

15-02-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that total revenues were…

BiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronZaltrap

Sanofi's Zaltrap gets EU approval for metastatic colorectal cancer

06-02-2013

In a second European approval within a matter of days, French drug major Sanofi (Euronext: SAN) said…

EuropeOncologyPharmaceuticalRegeneronRegulationSanofiZaltrap

Positive Ph III VELOUR results with Sanofi's Zaltrap

10-10-2012

French drug major Sanofi (Euronext: SAN) says that positive detailed results from the pivotal Phase III…

OncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Zaltrap gains US approval for metastatic colorectal cancer

06-08-2012

The US Food and Drug Administration on Friday approved French drug major Sanofi (Euronext: SAN) and US…

North AmericaOncologyPharmaceuticalRegeneronRegulationSanofiZaltrap

Sanofi and Regeneron mCRC drug Zaltrap misses goals but gets FDA priority

10-04-2012

The US Food and Drug Administration has granted priority review of the Biologics License Application…

BiotechnologyNorth AmericaPharmaceuticalRegeneronRegulationResearchSanofiZaltrap

1 to 9 of 12 results

COMPANY SPOTLIGHT

Menarini

Back to top